Betalin Therapeutics Overview
Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP). The EMP technology helps create connective tissue that enables the body's beta cells to function properly and produce adequate and functional insulin. Betalin Therapeutics licensed the novel EMP technology developed at the Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Cumulative Funding Raised Over Time ($)
$2.5MApr 2019
$2.5MFeb 2024
$3.1MJan 2022
Latest News
Growth-Positive
Revolutionizing Type 1 diabetes treatment: Israeli firm makes progress on micro pancreas
Betalin Therapeutics, an Israeli company, has announced progress in its development of a micro pancreas that could potentially free Type 1 diabetes patients from their dependency on insulin injections. The therapy is still in the preclinical trial stage. The company has achieved successful preclinical results both in vitro and on animals using islet cells. The next step is to achieve similar results with stem cells, which requires collaboration with other companies. The company aims to offer a new Type 1 diabetes therapy in the future.
CustomersPartnersExpand
growth-positive
https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-694626
The European Innovation Council (EIC) Fund has made a direct equity investment of €500,000 in Betalin Therapeutics, an Israeli company. The investment will fund human trials of a biological pancreas that produces insulin independently in the body, eliminating the need for further injections. The EIC Fund will appoint an observer to Betalins Board of Directors to support product development. This investment follows €3.6 million in grants received by Betalin Therapeutics from the EUs Horizon 2020 R&D program. To date, the company has raised NIS 45 million in capital investments and grants. Betalin Therapeutics aims to treat type 1 diabetes and 25% of type 2 diabetes patients who require insulin injection.
Investment
growth-negative
קמן קפיטל מנסה שוב: תמזג את חברת הביומד בטאלין תמורת 75% בחברה
קמן קפיטל, a publicly traded company, has signed a non-binding memorandum of understanding with a private company called בטאלין, which develops a medical product for the treatment of diabetes. This is the fourth merger attempt by קמן קפיטל in the past two years. The merger will be done through a stock swap, with בטאלין shareholders transferring their holdings to קמן קפיטל in exchange for קמן קפיטל stocks and options. The completion of the deal is subject to various conditions, including approval from the relevant authorities and a minimum cash balance in קמן קפיטלs treasury.
Acquisition
growth-positive
Betalin Therapeutics receives EU equity investment for its alternative insulin therapy
Betalin Therapeutics will receive capital from the European Innovation Council (EIC) fund to increase human trials of a biological pancreas that can produce insulin in the body independently. The investment aims to eliminate the need for insulin injections and glucose testing. The trials will be conducted in collaboration with medical centers at the universities of Newcastle and Leeds in England. Betalin Therapeutics was founded in 2015 and focuses on developing technology to eliminate the need for insulin injections and glucose testing.
Investment
growth-negative
בטאלין תרפיוטיקס תנסה לגייס 18 מיליון שקל במטרה לעזור לחולי סוכרת
בטאלין תרפיוטיקס, a medical device company founded by entrepreneur Yehoshua Hershkovitz, is developing a medical product that aims to eliminate the need for insulin injections for diabetes patients. The company is in the early stages of product development and is seeking to raise 18 million shekels ($5.5 million) from institutional investors in Israel. The fundraising is led by Rosario Capital. The article highlights the companys efforts to develop a medical device that could have a significant impact on diabetes treatment.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $11.06M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 6 |
| Investors | 3 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | betalintherapeutics.com |
Locations
Jerusalem Bio Park (JBP) Minrav Bldg
HaBonim Street 1, Ramat Gan, Israel
Photos & Videos
1 item(s)
Betalin Therapeutics Business
Business models
B2B2C
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
Materials & SubstancesImplantsBiologicalsCellsTags (9)
bioconvergencediabetescell-therapybiological-therapyregenerative-medicinebiopharmaceuticalbiotechnologychronic-patientstreatmentsGeographic Markets
GlobalBetalin Therapeutics Financials
$11.06M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
6
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$2.5MApr 2019
$2.5MFeb 2024
$3.1MJan 2022
Private Equity Funding
Equity crowdfunding
Feb 2024
Undisclosed
Together We Invest (Lead)
A Round
Jan 2022
$565K
European Innovation Council (EIC)
Seed
Apr 2019
$2.5M
Undisclosed Investor(s)
Non-Equity Funding
GrantEvent
Jan 2021
$4M
EU Horizon 2020
GrantEvent
Sep 2020
$3M
EU Horizon 2020
GrantEvent
Jan 2016
$1M
Office of the Chief Scientist
Betalin Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$2.5MApr 2019
$2.5MFeb 2024
$3.1MJan 2022
All Events
Equity crowdfunding
Feb 2024
Undisclosed
Together We Invest (Lead)
A Round
Jan 2022
$565K
European Innovation Council (EIC)
Seed
Apr 2019
$2.5M
Undisclosed Investor(s)
GrantEvent
Jan 2021
$4M
EU Horizon 2020
GrantEvent
Sep 2020
$3M
EU Horizon 2020
GrantEvent
Jan 2016
$1M
Office of the Chief Scientist
Betalin Therapeutics News
16 articles
Growth-Positive
Revolutionizing Type 1 diabetes treatment: Israeli firm makes progress on micro pancreas
Betalin Therapeutics, an Israeli company, has announced progress in its development of a micro pancreas that could potentially free Type 1 diabetes patients from their dependency on insulin injections. The therapy is still in the preclinical trial stage. The company has achieved successful preclinical results both in vitro and on animals using islet cells. The next step is to achieve similar results with stem cells, which requires collaboration with other companies. The company aims to offer a new Type 1 diabetes therapy in the future.
CustomersPartnersExpand
growth-positive
https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-694626
The European Innovation Council (EIC) Fund has made a direct equity investment of €500,000 in Betalin Therapeutics, an Israeli company. The investment will fund human trials of a biological pancreas that produces insulin independently in the body, eliminating the need for further injections. The EIC Fund will appoint an observer to Betalins Board of Directors to support product development. This investment follows €3.6 million in grants received by Betalin Therapeutics from the EUs Horizon 2020 R&D program. To date, the company has raised NIS 45 million in capital investments and grants. Betalin Therapeutics aims to treat type 1 diabetes and 25% of type 2 diabetes patients who require insulin injection.
Investment
growth-negative
קמן קפיטל מנסה שוב: תמזג את חברת הביומד בטאלין תמורת 75% בחברה
קמן קפיטל, a publicly traded company, has signed a non-binding memorandum of understanding with a private company called בטאלין, which develops a medical product for the treatment of diabetes. This is the fourth merger attempt by קמן קפיטל in the past two years. The merger will be done through a stock swap, with בטאלין shareholders transferring their holdings to קמן קפיטל in exchange for קמן קפיטל stocks and options. The completion of the deal is subject to various conditions, including approval from the relevant authorities and a minimum cash balance in קמן קפיטלs treasury.
Acquisition
growth-positive
Betalin Therapeutics receives EU equity investment for its alternative insulin therapy
Betalin Therapeutics will receive capital from the European Innovation Council (EIC) fund to increase human trials of a biological pancreas that can produce insulin in the body independently. The investment aims to eliminate the need for insulin injections and glucose testing. The trials will be conducted in collaboration with medical centers at the universities of Newcastle and Leeds in England. Betalin Therapeutics was founded in 2015 and focuses on developing technology to eliminate the need for insulin injections and glucose testing.
Investment
growth-negative
בטאלין תרפיוטיקס תנסה לגייס 18 מיליון שקל במטרה לעזור לחולי סוכרת
בטאלין תרפיוטיקס, a medical device company founded by entrepreneur Yehoshua Hershkovitz, is developing a medical product that aims to eliminate the need for insulin injections for diabetes patients. The company is in the early stages of product development and is seeking to raise 18 million shekels ($5.5 million) from institutional investors in Israel. The fundraising is led by Rosario Capital. The article highlights the companys efforts to develop a medical device that could have a significant impact on diabetes treatment.
Investment
growth-positive
https://www.jpost.com/health-science/israels-betalin-therapeutics-plans-ipo-to-fund-diabetes-trials-642502
Betalin Therapeutics, an Israeli biotech firm, is planning an IPO to raise about $40 million in New York or London by the end of next year. The IPO is aimed at funding trials for the companys diabetes treatment, an artificial micro-pancreas that helps control blood sugar levels in diabetics. The company has received grants of 5.5 million euros from Europes Horizon 2020 program and is looking to start clinical trials by the end of next year. The treatment, which uses healthy donor cells implanted in the thigh, has the potential to eliminate the need for daily insulin injections. If successful, the final product is expected to be available in about five years and will have a one-time cost of approximately $50,000.
InvestmentPublic Trading
growth-positive
Micro-pancreas ready for UK trials says Israeli developer
Israeli firm Betalin Therapeutics is planning to test its implantable micro-pancreas in the UK. The device, which produces insulin in response to blood glucose levels, has already been tested on animals. The company plans to submit a request for human clinical trials in August, with the aim of having the product available by 2024. The micro-pancreas would last for two years and cost around $40,000 per implant. The company has received approximately £4.5m in grants from the EU and over £6m from investors in Israel, the US, and China.
InvestmentExpand
growth-positive
Israeli firm says pancreas to cure diabetes ready for trials in UK
Betalin Therapeutics, an Israeli firm, plans to initiate human clinical trials for its bio-artificial pancreas that could potentially cure diabetes. The company has developed a micro pancreas that can free diabetics from the need for insulin injections and blood sugar monitoring. Based on a biological scaffold adapted from pig lung tissue, the artificial pancreas contains beta cells that release insulin according to a patients blood sugar levels. Betalin Therapeutics aims to start human testing in early 2021 and expects to launch the product in the market by 2024. The companys unique technology has the potential to be used for other diseases as well. Diabetes affects over 460 million people worldwide, and this medical innovation could have a significant positive impact on the companys growth.
CustomersExpand
growth-positive
Israeli artificial pancreas may one day cure diabetes
Israeli startup Betalin Therapeutics is beginning the application process for clinical trials of its revolutionary artificial pancreas. The Engineered Micro Pancreas (EMP) aims to free patients suffering from severe types of diabetes from constantly monitoring blood-sugar levels and injecting insulin. Betalin is expecting a price of $50,000 per implant, with the global Type 1 diabetes market estimated to be worth $25.52 billion by 2024. The company is working on acquiring enough beta cells to fill the EMP, either from third parties or by making their own. Betalin has conducted animal trials and plans to raise an additional $5 million to complete regulatory work for human testing. If successful, it would take another five years before the EMP reaches the market.
InvestmentPartners
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-researchers-Cure-for-diabetes-within-the-next-five-years-603482
Betalin, a company developing a bio-artificial pancreas for diabetes treatment, has completed animal trials and is preparing for human clinical trials. The company has raised $3.5 million and is seeking an additional $5 million in funding. The bio-artificial pancreas is expected to cost around $50,000 per patient. Betalin is collaborating with clinics in several countries and has received a bi-national collaboration grant. The company aims to gradually roll out the technology to diabetic patients and eventually expand to treat other hormonal dysfunctions. Betalins founder and former CEO of Hadasit Ltd. and Gamida-Cell Ltd., Dr. Avi Treves, believes the technology will be more effective and economical than current treatments.
Investment
growth-positive
Insulin replacement co Betalin Therapeutics raises $2.5m
Betalin Therapeutics, an Israeli diabetes treatment developer, has raised $2.5 million in funding for its revolutionary treatment that aims to replace insulin therapy. The company provides a one-time transplant of the proprietary Engineered Micro Pancreas (EMP), which ensures continuous glucose-related insulin secretion. Betalin Therapeutics is also in talks with a Chinese pharmaceutical entity to enter the Chinese market. The company is addressing the issue of transplant rejection by signing a licensing agreement with the Hebrew University to use cannabis extracted molecules together with the EMP transplant. This will reduce the need for immunosuppressive drugs.
Investment
Finding a cure for diabetes
growth-positive
Betalin Therapeutics wins best biopharma startup award
Betalin Therapeutics, an Israeli company specializing in tissue engineering for curing diabetes, has been named the most innovative biopharma company of the year at the Tel Aviv MIXiii Biomed Conference. The company has developed the Engineered Micro Pancreas (EMP), a technology that provides glucose-regulated insulin secretion over extended periods of time. The EMP is prepared in the lab using a natural micro-scaffold and cellular components, and can be implanted anywhere in the body. Preclinical studies have shown promising results, with 70% of mice not needing further insulin injections for up to 90 days after implantation. Betalin Therapeutics is now in discussions with regulatory authorities for human clinical trials. The company aims to improve treatments for people with Type 1 and extreme cases of Type 2 diabetes.
Customers
growth-positive
Betalin Therapeutics Wins Startup Competition at MIXiii Biomed 2017
Betalin Therapeutics, a biotech company specializing in tissue engineering for curing diabetes, was chosen as the most innovative biopharma company of the year at a conference. They develop the Engineered Micro Pancreas (EMP), a technology that provides significant levels of glucose-regulated insulin secretion over extended periods of time. The goal is to supply efficient treatment to diabetics by implanting the engineered pancreas that can detect blood sugar levels. Preclinical trials in animal models have shown promising results, and the company is in discussions with regulatory authorities for human clinical trials. The standard treatment for diabetes is lifelong injections of insulin, and Betalin Therapeutics aims to improve existing treatments for people living with diabetes Type 1.
Investment
growth-positive
Betalin Aims To End Insulin Injections By Treating Type 1 Diabetes With Cell Transplants
Israeli biotech startup Betalin Therapeutics has developed a micro-scaffold that could potentially eliminate the need for insulin injections in Type 1 Diabetes patients. The micro-scaffold ensures that transplanted islet cells, which produce insulin, remain close to sources of nutrients, allowing for long-term functionality. The delivery method, called Engineered Micro Pancreas (EMP), has shown more efficient and regulated insulin production compared to beta cells without micro-scaffolding. The EMPs also become readily supplied with blood vessels and allow for the expansion of beta cells in culture, potentially treating a larger number of patients with a smaller number of islets. The micro-scaffold technique could have applications in other transplant therapies, including stem cell engraftment.
InvestmentExpand
growth-positive
Israeli biomed's novel technology could cure diabetes
Israeli biotech company Betalin Therapeutics is developing an engineered micro-pancreas (EMP) that can sustain significant levels of glucose-regulated insulin secretion from transplanted beta cells. If successful, this breakthrough has the potential to cure type 1 and severe forms of type 2 diabetes. The EMP is a micro biological scaffold that supports the survival and functionality of the transplanted cells. Betalin Therapeutics is preparing for clinical trials and has started a financing round of $2.5 million from private investors.
Investment
Betalin Therapeutics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 10 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Betalin Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Yotam Maman |
| Registrar ID | 515274272 |
| Crunchbase | betalin-therapeutics |
| Phone | +97229922025 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-08-13T00:00:00.000Z |
| Created | 2015-12-30T00:00:00.000Z |
| Claimed | Yes |